Last reviewed · How we verify

Simon Tremblay, PharmD, PhD — Portfolio Competitive Intelligence Brief

Simon Tremblay, PharmD, PhD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mycophenolic Acid Oral Product Mycophenolic Acid Oral Product marketed Immunosuppressant; IMPDH inhibitor Inosine monophosphate dehydrogenase (IMPDH) type II Immunology; Transplantation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chong Kun Dang Pharmaceutical · 1 shared drug class
  2. Hoffmann-La Roche · 1 shared drug class
  3. Novartis · 1 shared drug class
  4. University of North Carolina, Chapel Hill · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Simon Tremblay, PharmD, PhD:

Cite this brief

Drug Landscape (2026). Simon Tremblay, PharmD, PhD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/simon-tremblay-pharmd-phd. Accessed 2026-05-15.

Related